BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17623233)

  • 1. Does intraperitoneal therapy have a role in recurrent ovarian cancer?
    Cain JM
    World J Surg; 2007 Sep; 31(9):1821. PubMed ID: 17623233
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients.
    Cotte E; Glehen O; Mohamed F; Lamy F; Falandry C; Golfier F; Gilly FN
    World J Surg; 2007 Sep; 31(9):1813-1820. PubMed ID: 17629740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
    Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
    Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
    Munkarah A
    Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
    [No Abstract]   [Full Text] [Related]  

  • 6. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Locoregional recurrence of ovarian cancer: the place of surgery].
    Classe JM; Catala L; Marchal F; Ferron G; Dravet F; Pioud R; Descamps P
    Bull Cancer; 2004 Nov; 91(11):827-32. PubMed ID: 15582885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer.
    Sugarbaker PH
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):15-24. PubMed ID: 19124999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
    Cascales Campos P; Gil J; Parrilla P
    Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
    Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Standard of chemotherapy in ovarian cancer].
    Pfleiderer A; Meerpohl HG
    Chirurg; 1994 Jan; 65(1):18-22. PubMed ID: 8149794
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
    Dzhilavian GA; Vinokurov VL
    Vopr Onkol; 1984; 30(3):16-21. PubMed ID: 6424327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women.
    Delotte J; Arias T; Guerin O; Boulahssass R; Bereder I; Bongain A; Benchimol D; Bereder JM
    Acta Obstet Gynecol Scand; 2015 Apr; 94(4):435-9. PubMed ID: 25675854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reassessment of second-look operations (SLO) in the treatment of ovarian cancer].
    Ochiai K
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1303-9. PubMed ID: 2730043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
    Fagotti A; Costantini B; Vizzielli G; Perelli F; Ercoli A; Gallotta V; Scambia G; Fanfani F
    Gynecol Oncol; 2011 Aug; 122(2):221-5. PubMed ID: 21543112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of refractory ovarian cancer].
    Shparyk IaV; Tomych MV
    Lik Sprava; 1996; (10-12):41-7. PubMed ID: 9138811
    [No Abstract]   [Full Text] [Related]  

  • 18. Second-line treatment of first relapse recurrent ovarian cancer.
    Chua TC; Liauw W; Robertson G; Morris DL
    Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):465-71. PubMed ID: 21039382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperthermic intraperitoneal chemotherapy in the treatment for recurrent ovarian cancer].
    Giseĭnov KD; Beliaev AM; Senchik KIu; Maksimov SIa; Urmancheeva AF; Gafton GI; Mikaia NA; Beliaeva OA; Kireeva GS; Gorodnova TV; Matveeva NS
    Vopr Onkol; 2014; 60(3):343-7. PubMed ID: 25033688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy in epithelial ovarian cancer.
    Wang J; Li AJ; Karlan BY
    Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.